Evidence map›Paper›PMID 38192516›Full record

ArticleBreast cancer : basic and clinical research2024

Clinical Outcomes of Breast-Conserving Surgery with Synchronous 50-kV X-ray Intraoperative Partial Breast Irradiation in Patients Aged 64 Years or Older with Low-Risk Breast Cancer.

Kamran Salari, Andrew Glaza, Joseph S Lee, Neha Sarvepalli, Nayana Dekhne, Sayee H Kiran, Peter Y Chen, Joshua T Dilworth

Abstract read
In one paragraph

Article in Breast cancer : basic and clinical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kamran SalariDepartment of Radiation Oncology, Corewell Health East William Beaumont University Hospital, Royal Oak, MI, USA.
Andrew GlazaDepartment of Radiation Oncology Oakland University William Beaumont School of Medicine, Rochester, MI, USA.
Joseph S LeeDepartment of Radiation Oncology, Corewell Health East William Beaumont University Hospital, Royal Oak, MI, USA.
Neha SarvepalliDepartment of Breast Surgery, Premier Surgical Oncology at Miami Valley Hospital North Campus, Englewood, OH, USA.
Nayana DekhneDepartment of Breast Surgery, Corewell Health East William Beaumont University Hospital, Royal Oak, MI, USA.
Sayee H KiranDepartment of Breast Surgery, Corewell Health East William Beaumont University Hospital, Royal Oak, MI, USA.
Peter Y ChenDepartment of Radiation Oncology, Corewell Health East William Beaumont University Hospital, Royal Oak, MI, USA.
Joshua T DilworthDepartment of Radiation Oncology, Corewell Health East William Beaumont University Hospital, Royal Oak, MI, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Breast-conserving surgery with synchronous 50-kV X-ray intraoperative radiation therapy (TARGIT-IORT) is a convenient form of partial breast irradiation; however, the existing literature supports a wide range of local control rates. Objectives: We investigated the treatment effectiveness and toxic effects of TARGIT-IORT in a patient cohort aged 64 years or older with low-risk breast cancer. Design: Retrospective analysis. Methods: Patients who received breast-conserving surgery with synchronous TARGIT-IORT at a single institution from 2016 to 2019 were reviewed. Additional whole breast irradiation was recommended at the discretion of the treating radiation oncologist. Baseline patient demographics and treatment details were recorded. Acute and chronic toxicities, measured using the Common Terminology Criteria for Adverse Events version 3.0 or 4.0 and breast cosmetic outcomes, using the Harvard Cosmesis score, were recorded. Locoregional recurrence, distant metastasis, and overall survival were recorded, and 5-year rates were estimated using the Kaplan-Meier method. Results: 61 patients were included with a median follow-up of 3.5 years and median age of 72 years. Eight (13%) patients received additional whole breast irradiation, and fifty-four (89%) received adjuvant hormone therapy. There were no local, regional, or distance recurrences. One patient died of complications from COVID-19 infection. Grade 2 + acute and chronic toxicities were observed in 6 (12%) and 7 (14%) patients, respectively. One patient experienced a grade 3 acute toxicity. Cosmetic outcome was "excellent" or "good" in 45 (92%) patients. Conclusions: Breast TARGIT-IORT was well tolerated and conferred excellent disease control in this cohort of patients with low-risk breast cancer. While continued follow-up is required, TARGIT-IORT may be an appropriate treatment option for this population.

Indexed as

brachytherapybreast cancerbreast TARGIT-IORTIntraoperative radiation therapypartial breast irradiationTARGIT-IORT

Identifiers

PMID38192516
PMCPMC10771749

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.